Introduction: Despite the proven efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in lowering total and low-density lipoprotein cholesterol (LDL-C), many patients do not reach recommended lipid targets. This study compared pitavastatin, a new and highly effective statin, and simvastatin in patients at high risk of coronary heart disease (CHD). The primary objective was to demonstrate noninferiority of pitavastatin to simvastatin. Methods: The study was a phase 3, randomized, double-blind, double-dummy, parallel-group, active-controlled study conducted at 37 centers in five European countries. Following a dietary run-in period of 6-8 weeks, patients with primary hypercholesterolemia or combined dyslipidemia and at least two CHD risk factors were randomized 2:1 to receive pitavastatin 4 mg or simvastatin 40 mg once daily for 12 weeks. The primary efficacy variable was the change in LDL-C from baseline. Results: In total, 355 patients were randomized, 236 to pitavastatin and 119 to simvastatin; 330 patients (223 and 107, respectively) completed the study. In the pitavastatin group, mean (±SD) reduction in LDL-C concentrations from baseline was -44.0±12.8% compared with -43.8±14.4% in the simvastatin group. The adjusted mean treatment difference (simvastatin -pitavastatin) was 0.31% (95% confidence interval -2.47, 3.09; P=0.829), which was within the predefined noninferiority range. More than 80% of patients in each group reached recommended LDL-C targets. Pitavastatin provided a greater increase in highdensity lipoprotein cholesterol (HDL-C; 6.8% vs. 4.5%; P=0.083) and a significantly greater decrease in triglycerides (-19.8% vs. -14.8%; P=0.044) than simvastatin. Both treatments were well tolerated. Conclusion: Pitavastatin 4 mg is as effective as simvastatin 40 mg in lowering LDL-C in dyslipidemic patients at high risk of CHD, with additional effects on HDL-C and triglycerides. Therefore, pitavastatin may be appropriate for the management of dyslipidemic patients at high cardiovascular risk. 812 Adv Ther (2011) 28(9):811-823.
patients who were followed for a mean of 5 years, statins were shown to reduce the risks of major vascular events, cardiac mortality, and overall mortality by 21%, 19%, and 12%, respectively, for each mmol/L decrease in LDL-C. 1 Nevertheless, a significant proportion of dyslipidemic patients do not meet the lipid targets recommended in current consensus guidelines, despite treatment with statins. [2] [3] [4] [5] Thus, there is a need for more effective risk-management strategies to reduce the burden of cardiovascular mortality and morbidity associated with dyslipidemia. Such strategies could include the use of more aggressive initial therapy, more potent lipid-lowering agents, dose adjustment during treatment, or combination therapy using agents with different mechanisms of action.
Pitavastatin is a novel statin that has been shown to be more potent in lowering total cholesterol and LDL-C concentrations than simvastatin or pravastatin. [6] [7] [8] In contrast to other statins, it undergoes limited metabolism by cytochrome P450 isoenzymes 9, 10 and, hence, the potential for interactions with drugs metabolized by these enzymes is low. 11 The present study was performed to compare the efficacy of pitavastatin and simvastatin in lowering LDL-C concentrations in patients at high risk of coronary heart disease (CHD).
The primary objective was to demonstrate noninferiority of pitavastatin 4 mg once daily compared with simvastatin 40 mg once daily in reducing LDL-C concentrations. Secondary objectives were to assess the long-term efficacy of the two drugs in achieving the LDL-C targets recommended by the National Cholesterol Education Program (NCEP) Adult Treatment Panel III 12 and the European Atherosclerosis Society (EAS), 13 and to compare the effects of the two agents on other lipid measures and high sensitivity C-reactive protein (hs-CRP).
MATERIALS AND METHODS

Patients
Patients of either gender were eligible for inclusion in the study if they were aged 18-75 years and had primary hypercholesterolemia or combined dyslipidemia that was uncontrolled (LDL-C ≥3. 4 
Study Design
This was a phase 3, randomized, double-blind, double-dummy, parallel-group, active-controlled study conducted at 37 centers (predominantly in lipid clinics, cardiology clinics and university hospitals) in Denmark, the Netherlands, Spain, Sweden, and the United Kingdom. The study consisted of a 12-week initial treatment period (the core study) followed by a 44-week extension. This paper presents the results of the core study; the results of the extension phase will be reported separately.
Eligible patients entered a lead-in and washout phase of 8 weeks if they had previously received lipid-modifying therapy or 6 weeks if they had not previously received such therapy.
During this phase, and for the duration of the study, they followed a fat-and cholesterolrestricted diet according to EAS guidelines.
Patients received counseling to ensure that they adhered to this diet throughout the study.
On completion of the run-in period, patients were randomized in a 2:1 ratio to receive pitavastatin 4 mg or simvastatin 40 mg once daily. Randomization was performed using an interactive voice recognition system at each center. Patients randomized to pitavastatin started treatment at a dose of 2 mg, and the dose was increased to 4 mg after 4 weeks. In patients randomized to simvastatin, the initial dose was 20 mg, which was increased to 40 mg after 4 weeks. Treatment was given once daily in the evening, and all other lipid-modifying therapies were prohibited for the duration of the study. 
Safety and Tolerability
Treatment-emergent adverse events (TEAE), defined as any event with onset on or after the first dose of study drug, and serious TEAE were recorded throughout the study. All such events were coded by system organ class preferred terms using the Medical Dictionary for Regulatory Activities. Clinical laboratory safety assessments included routine blood chemistry, hematology, urinalysis, liver enzymes (alanine aminotransferase and aspartate aminotransferase), and creatine kinase (CK).
Other safety evaluations included physical examination, 12-lead electrocardiogram (ECG), and vital signs.
Statistical Analyses
The planned target size for the core study was 
RESULTS
Patient Flow and Baseline Characteristics
The first patient was enrolled on September 
Randomized to treament N=355
Pitavastatin n=236
Simvastatin n=119
Safety population n=233
Excluded: 1) .
Efficacy
LDL-C Concentrations
In the pitavastatin group, mean (±SD) Table 2 .
Attainment of EAS and NCEP Lipid Targets
Pitavastatin provided a significantly greater reduction in triglycerides than simvastatin (-19.8% vs. -14.8%; P=0.044), and there was also a greater increase in HDL-C with pitavastatin (6.8% vs. 4.5%), which was not statistically significant (P=0.083). There were no other significant differences in secondary lipid measures between the two groups. showed that simvastatin 40 mg reduced the incidence of myocardial infarction, stroke, and revascularization by about one-third in highrisk patients. The present study is, therefore, consistent with other studies, which suggest that pitavastatin is an effective and well-tolerated statin that is potentially suitable for primary or secondary prevention of CHD in a broad range of patients. 8, 9, 15 Further studies to assess morbidity and mortality are currently underway in Japan to determine the long-term efficacy and safety of pitavastatin.
Safety and Tolerability
A high proportion (81%-87%) of patients in both treatment groups achieved the LDL-C targets recommended in the NCEP and EAS guidelines. This figure is considerably higher than those reported in observational studies in Europe, in which approximately 55% of patients did not attain recommended LDL-C targets despite receiving lipid-modifying therapy. 3, 5, 16 This commonly obser ved discrepancy suggests that more aggressive therapy or dose adjustment may be necessary to achieve lipid synthesis, 18 there is evidence that pitavastatin increases HDL-C by increasing Apo-A1 and ATP-binding cassette transporter (also known as cholesterol efflux regulatory protein) levels. 19, 20 Further studies are needed to characterize the different effects of various statins on HDL-C concentrations, and their underlying molecular mechanisms.
Pitavastatin had a significantly greater effect than simvastatin on triglycerides, producing a mean reduction of approximately 20% from baseline. Triglycerides have been shown to be an independent risk factor for CHD, 21 Both treatments were well tolerated. The adverse event profiles of pitavastatin and simvastatin were similar, and there were no notable differences in the incidence of muscular adverse events (such as myalgia) and liver enzyme elevations. This is consistent with previous trials that have shown a favorable safety and tolerability profile of pitavastatin in a broad range of patients. 8, 9, 15 The limitations of this study should be 
